By Doug Macron

Following its acquisition of peptide immunotherapy firm Apthera in April, RXi Pharmaceuticals has terminated a number of its licenses from the University of Massachusetts Medical School for certain RNAi-related technologies, the company said.

Revealed in a filing with the US Securities and Exchange Commission this week, the move comes as little surprise given RXi's decision to pare down its RNAi programs following the Apthera deal.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.